Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes.
Understanding how diabetes and multiple myeloma interact in the same patient reveals opportunities to better manage treatment side effects and improve outcomes.
This review from MSK and Emory synthesizes evidence on the intersection of type 2 diabetes mellitus and multiple myeloma, covering shared risk mechanisms, prognostic impact of DM on MM outcomes, and overlapping drug toxicities (particularly with steroids and proteasome inhibitors). The authors identify key gaps requiring prospective study design to optimize outcomes in this dual-burden patient population.
What the study was
- Study design
- Narrative review
- Population
- Multiple myeloma patients with type 2 diabetes mellitus comorbidity
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood Cancer Journal
Why it surfaced
Clinically relevant review addressing an undercharacterized comorbidity intersection; review design limits novelty score; MSK authorship adds credibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.